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Abstract
Background: HIV-1 infected macrophages and microglia are long-lived viral reservoirs persistently producing viral
progenies. HIV-1 infection extends the life span of macrophages by promoting the stress-induced activation of the PI3K/Akt
cell survival pathway. Importantly, various cancers also display the PI3K/Akt activation for long-term cell survival and
outgrowth, and Akt inhibitors have been extensively searched as anti-cancer agents. This led us to investigate whether Akt
inhibitors could antagonize long-term survival and cytoprotective phenotype of HIV-1 infected macrophages.
Principal Findings: Here, we examined the effect of one such class of drugs, alkylphospholipids (ALPs), on cell death and
Akt pathway signals in human macrophages and a human microglial cell line, CHME5, infected with HIV-1 BaL or transduced
with HIV-1 vector, respectively. Our findings revealed that the ALPs, perifosine and edelfosine, specifically induced the death
of HIV-1 infected primary human macrophages and CHME5 cells. Furthermore, these two compounds reduced
phosphorylation of both Akt and GSK3b, a downstream substrate of Akt, in the transduced CHME5 cells. Additionally,
we observed that perifosine effectively reduced viral production in HIV-1 infected primary human macrophages. These
observations demonstrate that the ALP compounds tested are able to promote cell death in both HIV-1 infected
macrophages and HIV-1 expressing CHME5 cells by inhibiting the action of the PI3K/Akt pathway, ultimately restricting viral
production from the infected cells.
Significance: This study suggests that Akt inhibitors, such as ALP compounds, may serve as potential anti-HIV-1 agents
specifically targeting long-living HIV-1 macrophages and microglia reservoirs.
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Introduction
Targeting the actions of Human Immunodeficiency Virus Type
1 (HIV-1) proteins is currently a major anti-viral strategy that has
led to effective controls of HIV-1 replication and pathogenesis.
Unfortunately, this anti-HIV-1 strategy becomes ineffective due to
the robust evolution and escape capacity of HIV-1, in which viral
populations resistant to the currently available antiviral agents are
selected. New anti-HIV-1 strategies which may avoid this viral
escape are being extensively researched, and one promising
strategy is to target host factors and cellular mechanisms that HIV-
1 hijacks for its replication and pathogenesis.
HIV-1 infected macrophages exhibit extended life spans,
allowing these cells to become long-lived HIV-1 reservoirs that
persistently produce virus [1]. In addition, HIV-1 infected human
microglia, resident macrophages of the central nervous system
(CNS), isolated from patients displayed enhanced survival
compared to uninfected microglia isolated from the same patients
[2]. Importantly, it is known that HIV-1 infected macrophages
and microglia secrete nitric oxide and various toxic viral proteins,
such as gp120 and Tat, establishing cytotoxic extracellular
environments near the infected cells [2]. Numerous studies
reported that in the brain, these HIV-1 related toxic molecules
induce the death of nearby neurons, ultimately leading to HIV-
associated neurodegenerative diseases (HAND) in HIV-1 infected
patients [3,4]. However, it is not clearly understood how HIV-1
infected macrophages and microglia are able to live for a long
period of time and persistently produce viral progenies while these
infected cells are also constantly exposed to the same cytotoxic
environments that kill the nearby neurons.
To understand the paradox between the long-lived survival
phenotype of HIV-1 infected macrophages and the constant
exposure of the cells to the toxic extracellular conditions, we
hypothesized that HIV-1 may activate cellular pathways related to
cell survival in infected macrophages and microglia. Indeed, we
recently reported that HIV-1 infection triggers the activation of
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phages and renders these cells resistant to cytotoxic insults [5]. In
normal cells without exposure to cellular insults, this pathway
remains inactivated by its negative regulator, PTEN [6]. We also
demonstrated that the HIV-1 induced cytoprotection is initiated
by the expression of an HIV-1 accessory protein, Tat, which
lowers the PTEN level in infected macrophages and a human
microglia cell line, CHME5 [5]. In the absence of negative
regulation of the PI3K/Akt pathway by PTEN, HIV-1 infected
macrophages may proactively react to stressful cytotoxic extracel-
lular environments established by the virus-induced chemicals,
ultimately elevating their chance of survival.
The PI3K/Akt pathway is also commonly activated in many
cancer cells and promotes their survival and outgrowth [7]. Genetic
inactivation of the PTEN function, which is oncogenic, activates the
PI3K/Akt pathway [8,9]. Due to the direct mechanistic connection
between activation of the PI3K/Akt pathway and cancer, various
attempts to screen inhibitors of key enzymes of the pathway such as
PI3K and Akt kinases, have been made [10,11]. Among them,
alkylphospholipds (ALPs) have been tested for their anti-cancer
effect, and indeed miltefosine was recently found to be effective in
thetreatmentofcutaneousbreastcancermetastases[12].ALPs,also
termed antitumor lipids, have been found to display anti-neoplastic
effects in various tissue culture and small animal models [11,13,
14,15,16]. Their mechanisms of action involve regulation of
multiple cellular events related to cell proliferation, cell death and
cell survival [13,15,16,17]. Our recent study reported that
miltefosine is able to prevent HIV-1 infected macrophages from
activating the PI3K/Akt pathway, and specifically induces death of
HIV-1 infected macrophages upon exposure to insults, ultimately
terminating viral production [5]. However, the mechanism by
which miltefosine counteracts the PI3K/Akt pathway in HIV-1
expressing macrophages remains to be explored.
In this report, we investigated whether the ALP compounds,
perifosine and edelfosine, can specifically inhibit the activation of
Akt kinase activity in HIV-1 expressing macrophages. Indeed, we
demonstrate that perifosine and edelfosine inhibit both the
activation of Akt and the kinase activity of Akt in HIV-1
expressing human microglia cell lines, and perifosine effectively
induces the death of HIV-1 infected macrophages.
Methods
Cells, plasmids, and viruses
Primary human monocyte-derived macrophages were isolated
from human buffy coats (New York Blood Center) and differenti-
ated as previously described [5]. M-tropic HIV-1 BaL was provided
from Zeptometrix (Buffalo, NY) and VSV-G pseudotyped HIV-1
vector (DHIV-GFP) expressing EGFP and all HIV-1 proteins
except Nef and Env were prepared as described [5]. Vector titers
were determined with CHME5, a human fetal microglia cell line
[18], and the p24 ELISA was performed for each vector or virus
preparation following the manufacturer’s protocol. pTat101 is a
pcDNA3.1+Hygromycin (Invitrogen) derivative expressing a 101
amino acid HIV-1 Tat cDNA derived from the YU-2 M-tropic
HIV-1 strain [19]. A CHME5 subline that stably expresses full-
length Tat (pTat101) and a control cell line (pCDNA3.1-Hygro)
were previously selected [19]. The concentrations of cycloheximide
(CHX) and E. coli serotype O26:B6 lipopolysaccharide (LPS)
(Sigma) used were described in Figure legends.
Cell survival assays
CHME5 cells were exposed to LPS (50 mg/ml)/CHX (10 mg/
ml), and sodium nitroprusside (SNP) (Sigma) was used at 100 mM
for treatment of macrophages. Two methods were employed to
monitor the dead cell populations. First, the CHME5 sublines
were trypsinized and mixed with 0.4% Trypan blue solution
(Gibco) at a 1:1 dilution, and the number of blue (dead) cells was
calculated. Second, CHME5 cells and macrophages transduced by
the HIV-1 vector expressing GFP were analyzed with ethidium
homodimer included in the Live/Dead-Viability/Cytotoxicity kit
(Molecular Probes) to stain the dead cells as per the manufacturer’s
protocol. Images were taken at a 1006magnification at 24 hours
post-treatment using a fluorescence microscope (Zeiss). Each assay
was performed at least in triplicate. In each assay, three different
pictures were taken and .300 transduced green cells (.100 cells
per picture) were counted. The number of dead (red) cells per
counted transduced (green) cells was used to determine percentage
of cell death.
Assays for phosphorylation and kinase activity of Akt
CHME5 (1610
6) cells transduced with pseudotyped HIV-1
vector (,90% transduction) and CHME5 sublines were treated
with LPS (50 mg/ml)/CHX (10 mg/ml) in the presence or absence
of ALP compounds for 24 hours. Cells were lysed using ELB lysis
buffer before performing the western blot-based Akt kinase activity
assay (Cell Signaling) or ELISA-based Akt assay kit (Calbiochem)
as per the manufacturers’ protocols. The same lysates were used
for the western blot for total and phospho-GSK3b as described
[5]. Ratios between the band intensities of phosphorylated and
non-phosphorylated Akt and GSK3b levels were analyzed using
ImageJ software (NIH).
Virus production assay and live/dead assay with infected
macrophages
Primary human macrophages (8610
4) were infected with HIV-
1 BaL (7610
4 pg p24). 24 hours post-infection, cells were washed
with Dulbecco’s phosphate buffered saline to eliminate the
presence of excess virus. After washing, cells were cultured either
in media alone, media containing SNP (100 mM), or media
supplemented with 20 mM Perifosine (Cayman Chemical). Infect-
ed macrophages were cultured for 12 days, and viral production at
12 days post infection was measured by p24 ELISA (Perkin Elmer)
according to the manufacturer’s protocol. Cells were analyzed for
the induction of cell death using the live/dead assay as described
above. Merged (red + green + bright field) images are shown at
1006magnification. Green cells represent viable cells while those
with red nuclei correspond to dead or dying cells.
Results
Effect of ALP compounds on Akt activation and
phosphorylation in HIV-1 expressing CHME5 cells
We previously reported that HIV-1 expression promotes the
activation of cellular signals involved in the PI3K/Akt pathway in
CHME5 cells (e.g. GSK3b phosphorylation, reference 5: Figure S1)
and primary human macrophages [5], which explains their elevated
cellsurvivalphenotypes.WhileALPcompounds,whicharepotential
Akt inhibitors, affect cellsurvival signals inseveral cancer cell models
[13,15,16,17], it has not been tested if the ALP compounds also
affect the cell survival signaling in HIV-1 infected cells. Thus, first,
ALP compounds were examined for the ability to inhibit the
activation of Akt kinase in CHME5 cells, either transduced by the
DHIV-GFP vector or expressing Tat protein. CHME5 cells were
transduced by an HIV-1 vector, DHIV-GFP, expressing all HIV-1
proteinsexceptEnvandNef;thenefgenewasreplacedwithGFP[5],
yielding .90% transduction as determined by fluorescence-
activated cell sorting (FACS) for GFP expression. At two days post
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ride (LPS, 50 mg/ml) and cycloheximide (CHX, 10 mg/ml), which
impose stress on the cells, in the presence or absence of three
different ALP compounds, edelfosine, perifosine or miltefosine (see
Figure 1 for their chemical structures), for 24 hours. Lysates were
then prepared and applied to western blots for examination of both
total Akt and serine-473 phospho-specific Akt levels. Ratios between
phospho-specific Akt and total Akt were determined as marked in
Figure 2A. Note that since treatment with LPS/CHX alone induced
a significant amount of death of the untransduced/control cells
within 24 hours as previously reported [19], the analysis of the
untransduced cells in this experiment was omitted.
As shown in Figure 2A, the DHIV-GFP vector-transduced cells
exhibit a low level of Akt phosphorylation in the absence of LPS/
CHX treatment (‘‘C’’), while LPS/CHX treatment (‘‘L’’) signif-
icantly induced the phosphorylation of Akt in the vector-
transduced CHME5 cells. However, upon treatment with both
LPS/CHX and ALP compounds, the phosphorylation of Akt in
transduced cells decreased, suggesting that the ALP compounds
effectively block the LPS/CHX stress-induced Akt phosphoryla-
tion in the HIV-1 vector-transduced CHME5 cells.
We previously reported that the expression of Tat is responsible
for the cytoprotective effect of HIV-1 expressing macrophages and
CHME5 cells [5,19], which is supported by our previous
observation that Tat expression elevates the phosphorylation of
Akt and GSK3b in CHME5 (Figure S2). Thus, we tested if the
ALP compounds also block the stress-induced Akt phosphorylation
of the CHME5 sublines that were previously constructed by stably
transfecting with pCDNA3.1-hygro [(2) Tat] or pTat101 [(+) Tat]
expressing the 101 amino acid M-tropic YU-2 Tat protein [19]. In
this test, an ELISA-based phospho-Akt assay was employed to
determine the level of Akt phosphorylation. The lysates of (+) Tat
CHME5 subline cells were prepared in the presence of LPS/CHX
alone or both LPS/CHX and an ALP compound. Lysates,
normalized by protein level, were applied for the ELISA-based
phospho-Akt assay. Again, note that the control (2) Tat cells were
not analyzed in this experiment because the LPS/CHX treatment
very effectively induces the death of the control cells as reported
previously [19] and shown later in this study. As shown in
Figure 2B, the LPS/CHX treatment significantly elevated the Akt
phosphorylation in the (+) Tat subline cells, supporting that stress-
induced cell survival activation in the Tat expressing CHME5.
However, the treatment with the ALP compounds alone did not
affect the Akt phosphorylation. It is also important to note that
HIV-1 vector transduction alone does not increase the Akt
phosphorylation in the absence of the LPS/CHX (Figure 2).
However, as shown in Figure 2B, indeed, the treatment with the
ALP compounds reduced the LPS/CHX induced Akt phosphor-
ylation in the Tat expressing cells, suggesting the ALP compounds
effectively counteract the stress-induced Akt phosphorylation.
Effect of ALP compounds on kinase activity of Akt in
CHME5 cells
Phosphorylation of Akt activates its kinase activity, allowing the
enzyme to phosphorylate a number of downstream effectors such
as GSK3b [20]. We investigated if the ALP compounds, which
reduced the phosphorylation of Akt kinase, also block the kinase
activity of Akt. For this, the phosphorylation of GSK3b,a
downstream substrate of Akt kinase was monitored. The same
CHME5 cell lysates used for examining the phosphorylation of
Akt kinase (Figure 3) were analyzed for determining both total and
phosphorylated GSK3b. As shown in Figure 3A, the LPS/CHX
stress elevated the phosphorylation of GSK3b in the DHIV-GFP
vector transduced, compared to the untreated cells. However, the
treatments with perifosine, edelfosine or miltefosine reduced the
phosphorylation of GSK3b even in the presence of LPS/CHX,
compared to the LPS/CHX alone treated cells. In addition, as
shown in Figure 3B, the three ALP compounds reduced GSK3b
phosphorylation to the control cell level in the (+) Tat CHME5
subline cells even in the presence of the LPS/CHX stress. The
data shown in Figure 3 support that perifosine, edelfosine, and
miltefosine block the kinase activity of Akt in both HIV-1- and
Tat-expressing cells. These data mechanistically postulate that the
three ALP compounds tested may be able to abolish the
cytoprotective phenotype of HIV-1 and Tat-expressing CHME5
cells.
Counteracting cytoprotective phenotype of CHME5
expressing HIV-1 proteins or Tat by ALP compounds
Next, since the data presented in Figures 2 and 3 demonstrated
that the ALP compounds inhibit both stress-induced Akt activation
and Akt kinase activity, we tested if the ALP compounds
counteract the elevated survival capability of the CHME5 cells
expressing HIV-1. First, CHME5 cells were transduced by DHIV-
GFP (D3) and cultured for 48 hours, yielding .90% transduction
as determined by FACS for the GFP expression. Cells were then
exposed to LPS and CHX, which impose stress on the cells, for
24 hours in the presence and absence of the ALP compounds
(edelfosine and miltefosine, Figure 4A). Cells were stained with
ethidium homodimer for visualization of dead cells; the amount of
dead cells (red) among transduced cells (green) was determined. As
shown in Figure 4A, the LPS/CHX treatment induced cell death
(,20%) in the cells alone, and induced little death among
transduced cells (,2%), supporting the cytoprotective effect of
Figure 1. Structures of alkylphospholipid compounds used in
this study.
doi:10.1371/journal.pone.0013121.g001
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CHME5 cells transduced with DHIV-GFP vector (D3) giving ,90% transduction and (B) Tat expressing CHME5 subline cells were exposed to LPS
(50 mg/ml) and CHX (10 mg/ml) (‘‘L’’) in the presence and absence of 25 mM ALP compounds for 24 hours. For the transduced cells (A), the ratios
between the levels of phospho-specific and total Akt proteins in the western blots were determined in triplicate, and these ratios were normalized by
the ratio in the HIV-1 vector transduced control cells without any treatment (‘‘C’’). For the Tat expressing subline cells (B), the phospho-Akt levels were
determined by ELISA-based assay, and the phospho-Akt level in the HIV-1 vector transduced control CHME5 cells with no treatment was used for
signal normalization. L: LPS and CHX stress treatment, PF: perifosine, EF: edelfosine, MF: miltefosine.
doi:10.1371/journal.pone.0013121.g002
Figure 3. Inhibition of Akt kinase activity by ALP compounds in HIV-1 vector transduced or Tat expressing CHME5 cells. (A) CHME5
cells transduced with DHIV-GFP giving ,90% transduction and (B) Tat expressing CHME5 subline cells were exposed to LPS (50 mg/ml)/CHX (10 mg/
ml) in the presence or absence of the ALP compounds for 24 hours. Ratios between the levels of phospho-specific and total GSK3b proteins were
determined and normalized as described in Figure 2. C: control cells not treated with stress, L: LPS and CHX stress treatment, PF: perifosine, EF:
edelfosine, MF: miltefosine.
doi:10.1371/journal.pone.0013121.g003
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miltefosine alone did not significantly induce cell death in the
transduced cells cultured in the absence of LPS/CHX, suggesting
that these compounds do not induce nonspecific cytotoxicity, at
least at the concentrations used in Figure 4. However, upon
treatment with both edelfosine or miltefosine and LPS/CHX, a
high proportion of the transduced cells underwent cell death,
suggesting that the ALP compounds effectively abolished the
cytoprotective effect of HIV-1 transduction in CHME5 cells.
Next, we tested if the ALP compounds also block the Tat-
induced cytoprotective phenotype of CHME5 cells, which was
previously reported [5]. In this experiment, cell death of these two
sublines was monitored after treatment of perifosine, edelfosine,
and miltefosine in the presence and absence of LPS/CHX with a
Trypan blue exclusion assay. As shown in Figure 4B, the (2) Tat
control CHME5 cells showed a significant cell death (,40%) by
the LPS/CHX treatment, whereas the (+) Tat CHME5 cells
displayed a strong protection (,5% cell death) against the LPS/
CHX insults, supporting the cytoprotective effect of Tat in
CHME5 cells. When treated with perifosine, edelfosine, or
miltefosine alone (Figure 4B), both subline cells displayed a
background level of cell death, suggesting that these three ALP
compounds do not induce nonspecific cytotoxicity in this cell line
system at the concentrations used in this experiment. However,
upon treatment with both LPS/CHX and the ALP compounds
(Figure 4B), the (+) Tat cells lost the Tat-induced cytoprotective
effect against the LPS/CHX insult and became sensitive to the
LPS/CHX treatment. These data support that all three ALP
compounds were able to block the cytoprotective function of Tat
in CHME5 cells. Interestingly, the (2) Tat control subline treated
with both ALP compounds and LPS/CHX still showed the same
high cell death as observed with the treatment of LPS/CHX
alone, and thus this indicates that, in contrast to the (+) Tat cells,
the ALP compounds do not sensitize the (2) Tat cells to the LPS/
CHX insult.
Next, ALP compound-induced sensitization of the (+) Tat
CHME5 subline to LPS/CHX was tested for concentration
dependent effects. The amount of cell death of (+) Tat cells was
determined at 0, 5, 15 and 25 mM of perifosine or edelfosine in the
presence of the fixed amount of the LPS/CHX stress. As shown in
Figure 4C, the amount of death of the (+) Tat subline cells
gradually increases when the concentrations of perifosine and
edelfosine increase, and at 25 mM, the ALP compounds re-
sensitize the Tat (+) CHME5 cells to the LPS/CHX. Thus, the
data shown in Figure 4 support that the ALP compounds induce
the loss of the cytoprotective phenotype of both HIV-1 transduced
and Tat expressing CHME5 cells.
Induction of death in HIV-1 infected primary human
macrophages by perifosine
Next, we examined if perifosine can also counteract the
cytoprotective phenotype of primary human macrophages infected
with HIV-1. Importantly, we previously reported that indeed,
HIV-1 infected macrophages display activation of Akt (GSK3b
phosphorylation and Akt migration to the membrane), and
miltefosine was able to effectively counteract the pro-survival
phenotype of the HIV-1 infected macrophages [5]. In addition, in
this investigation, we chose perifosine (PF) for its clinical
significance; PF has been tested through Phase 2 trials for its
anti-cancer effect [21].
Figure 4. Counteracting effect of ALP compounds against the
cytoprotective phenotype of HIV-1 or Tat expressing CHME5
cells. (A) Death of CHME5 cells untreated (‘‘Control’’) or treated with
LPS (50 mg/ml) and CHX (10 mg/ml) (‘‘LPS/CHX’’) was determined by
staining with ethidium homodimer (red) at 24 hours post treatment.
CHME5 cells were also transduced by DHIV-GFP (‘‘D3’’, .90%
transduction), and treated with LPS/CHX in the presence and absence
of 25 mM edelfosine (‘‘EF’’) or miltefosine (‘‘MF’’) at 48 hours post
transduction. The dead cells (red) among the transduced cells (green)
were determined to calculate the cell death percentage. (B) CHME5 (2)
and (+) Tat subline cells were treated with LPS/CHX for 24 hours in the
presence or absence of edelfosine (25 mM), perifosine (25 mM) or
miltefosine (50 mM). Dead cells were stained with Trypan blue. (C) Dose-
dependent cell death of the (+) Tat CHME5 subline by edelfosine,
perifosine, and miltefosine treatment in the presence of LPS (50 mg/ml)
and CHX (10 mg/ml). The percent cell death of the (+) Tat cells treated
with both LPS/CHX and different concentrations of the ALP compounds
were determined and compared to the percent cell death of the (2) Tat
control cells treated with LPS/CHX alone, which gave 39% cell death.
doi:10.1371/journal.pone.0013121.g004
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with 7610
4 pg p24 of M-tropic HIV-1 BaL, which is MOI .5a s
previously reported [5], and the infected macrophages were
cultured for 12 days in various conditions shown in Figure 5.
Under these culture conditions, more than 95% of the
macrophages were infected at 12 days post infection as determined
by the p24 intracellular staining (data not shown). The cells were
then analyzed for live and dead phenotypes by staining with live
(green) and dead (red) cell specific dyes. In this study, three
concentrations of perifosine were used, 1, 5 and 20 mM, and
100 mM sodium nitroprusside (SNP) which is a nitric oxide
producer, well known to be an HIV-1 related cellular stress [22].
As shown in Figure 5A and 5B, HIV-1 infected macrophages
showed effective cell survival (green cells) for 12 days in the
absence of SNP and perifosine (media alone), which is contrasted
to the HIV-1 infected CD4
+ T cells known to undergo cell death
within a few days post infection. Under this culture condition, the
basal level of death of HIV-1 infected macrophages was ,10%.
Furthermore, HIV-1 infected macrophages displayed strong
survival (green) with only a slight increase (,2-fold) of the basal
cell death (Figure 5A and 5B) even in the presence of the 100 mM
SNP stress which normally induces .90% cell death in the
uninfected macrophages [19], confirming the cytoprotective
phenotype of the HIV-1 infected macrophages. When the infected
macrophages were treated with the three different concentrations
of perifosine without SNP, the cells still exhibited only background
cell death (Figure 5A and 5B), suggesting that perifosine does not
impose nonspecific cytotoxicity on the infected macrophages at
these concentrations. However, simultaneous treatment of perifo-
sine and SNP to the culture revealed elevated death compared to
the perifosine or SNP singly treated control cells (Figure 5A).
Moreover, cell death increased in a dose-dependent manner with a
rise in perifosine concentration in the presence of SNP (Figure 5B).
Thus, the data in Figure 5 suggest that perifosine induces the death
of HIV-1 infected macrophages, specifically when the cells were
exposed to cellular stress which does not normally induce the
death of the HIV-1 infected macrophages.
Effect of ALPs on HIV-1 production in macrophages
The data presented in Figure 5 demonstrate that perifosine
induces death of HIV-1 infected macrophages when they are
exposed to a level of cellular stress which alone does not kill the
HIV-1 infected macrophages. Thus, finally, we tested if perifosine
is able to reduce viral production from HIV-1 infected
Figure 5. Anti-cytoprotective activity of perifosine in HIV-1 infected primary human macrophages. Primary human monocyte-derived
macrophages isolated from blood donors were infected with HIV-1 Bal at MOI 5, and cultured for 12 days in the presence and absence of sodium
nitroprusside (SNP, 100 mM) and/or several concentrations of perifosine. Note that 100 mM SNP induces nearly 95% death of uninfected human
macrophages [5]. (A) Cells were stained with ethidium homodimer and calcein to distinguish between dead (red) and live (green) cells, respectively,
on day 12. Images were taken with a fluorescence microscope, and the images shown (merged bright, red, and green fields) are representatives of 3
experiments conducted in duplicate. (B) Percent cell death was determined by counting dead and live cells. The values are averages of the duplicates
for all conditions performed with macrophages isolated from three separate healthy blood donors. C: infection with no treatment, PF: perifosine.
doi:10.1371/journal.pone.0013121.g005
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were infected with a high MOI of M-tropic HIV-1BaL, and
monitored viral production by a p24 ELISA assay after 12 days of
culture in the presence or absence of perifosine (20 mM) and SNP
(100 mM). As shown in Figure 6, SNP treatment reduced viral
production only by ,50%, which is consistent with the previous
report that the SNP treatment usually decreases viral production
50–70% while the cell death assay showed ,5% death of the HIV
infected macrophages (Figure 5) [5]. Additionally, 20 mM
perifosine alone only slightly affected viral production. However,
when HIV-1 infected macrophages were exposed to both
perifosine and SNP, a 9-fold reduction of viral production was
observed, which should be a consequence of the significant cell
death in the HIV-1 infected macrophages (Figure 5). Therefore,
these data observed with primary human macrophages and
infectious HIV-1 support the idea that perifosine effectively
reduces HIV-1 production by antagonizing the stress-induced
cytoprotective phenotype of the HIV-1 infected macrophages.
Discussion
Targeting host factors that are utilized for the life cycle of HIV-
1 is a highly attractive anti-viral strategy. Unlike current anti-viral
treatments targeting viral proteins, such as reverse transcriptase,
protease and integrase, this strategy can minimize viral escape.
One major obstacle in targeting host factors is that many which
are utilized by HIV-1 are also essential to the host. Thus the
conditionally required or non-essential host factors are better
candidates as anti-HIV-1 targets. Indeed, the Akt cell survival
pathway is conditionally activated only upon exposure to cytotoxic
insults or in abnormal cells that require exceptional survival
techniques, such as cancer cells.
Importantly, it is well known that HIV-1infected macrophages
and microglia establish toxic extracellular environments by
persistently secreting viral cytotoxic proteins (e.g. gp120 and
Tat) and chemicals (e.g. NO), and this toxic environment induces
death of nearby neurons in the CNS, leading to HIV-1 associated
neurodegenerative diseases [2]. Ironically, even with the
establishment of extracellular cytotoxic conditions HIV-1
infected macrophages exhibit an extended life span, (unlike
infected CD4
+ T cells which undergo cell death) and serve as
long-term HIV-1 reservoirs [1,19,23]. Thus it is highly plausible
that the pro-activation capability of the stress-induced PI3K/Akt
cell survival pathway by HIV-1 infection can effectively protect
the infected macrophages from the toxic local environments
generated by their own proteins and chemicals, leading to long-
lived viral reservoirs.
In this report, we demonstrated that the ALP compounds,
edelfosine, perifosine and miltefosine, were able to inhibit HIV-1
induced Akt activation, leading to the death of HIV-1 expressing
macrophages and CHME5 cells. However, edelfosine treatment of
primary human macrophages proved to be significantly cytotoxic
at concentrations as low as 1 mM (data not shown). The precise
mechanism of action of ALP compounds against Akt kinase
remains unclear, though multiple reports demonstrated that the
compounds reduce Akt activation in tumor tissue culture models
[13,14,15,16]. While our study focused on the inhibitory function
of ALP compounds against activation of the Akt cell survival
pathway, we do not exclude a possibility that the inhibitory effect
of these two ALP compounds on the cytoprotective phenotype of
HIV-1 expressing macrophages and CHME5 cells may also result
from other closely related cellular events such as the activation of
the apoptotic pathway and inhibition of the anti-apoptotic
pathway. In fact, whether HIV-1 infection mechanistically affects
apoptosis-related events in macrophages has not been tested,
presumably because unlike CD4
+ T cells undergoing cell death
following G2 arrest, the cell death phenotype of HIV-1 infected
macrophages is absent (these cells actually live longer). Since we
employed ethidium homodimer which primarily stains necrotic
cells, not living or apoptotic cells, our study monitored the necrosis
rate of the HIV-1 infected macrophages upon exposure to the
ALP compounds. Indeed, the effect of HIV-1 infection as well as
the ALP treatment on apoptosis and anti-apoptosis can be
investigated in the future. In addition, while our data demonstrate
that the ALP compounds effectively inhibit the HIV-1 and Tat-
induced Akt activation/phosphorylation in the CHME5 model, it
still remains to be confirmed that the ALP compounds also block
Akt phosphorylation in HIV-1 infected macrophages. This is
mainly due to technical issues: we found that the primary human
macrophage lysates, particularly, after ALP treatment, were not
applicable to various methods of Akt activity including western
analysis.
The ALP compounds investigated in this study are known to
be well-tolerated in various pre-clinical trials [24] and to do little
harm in normal cells in various in vitro models; this could be
due to the fact that normal cells do not activate the PI3K/
Akt pathway unless they are exposed to extracellular insults.
Importantly, many studies, especially from anti-Leishmania
research, demonstrated that ALP compounds are effectively able
to penetrate the blood-brain barrier (BBB) [25,26]. Considering
that HIV-1 infected macrophages and microglia in the brain
play a key role in HAND, this BBB penetration feature of ALP
compounds is very important in terms of their potential clinical
application. However, it is clear that further investigations and
evaluations of the ALP compounds as anti-HIV agents need to
be conducted.
Figure 6. Inhibition of HIV-1 production from primary human
monocyte-derived macrophages by perifosine. Primary human
monocyte-derived macrophages were infected and cultured for 12 days
in the presence and absence of sodium nitroprusside (SNP, 100 mM)
and/or perifosine (20 mM), and the p24 levels of the supernatants on
the 12
th day of the culture were determined. The p24 level at day 12 for
each condition was normalized by the p24 level (86 pg/ml) of the
media only control (no treatment).
doi:10.1371/journal.pone.0013121.g006
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Figure S1 Akt and GSKb phosphorylation by DHIV-GFP in
CHME5cells. 16105 CHME5 cells were transduced by DHIV-
GFP as described in Figure 2, and the cell lysates were analyzed by
western blots for total (t) and phospho (p) specific Akt and GSK3b.
The fold differences in the signals are marked.
Found at: doi:10.1371/journal.pone.0013121.s001 (1.56 MB TIF)
Figure S2 Akt and GSKb phosphorylation by Tat expression
in CHME5 cells. Lysates from 16105 CHME5 sublines with
pCDNA3.1-hygro (-) or pTat101 (+) cells were analyzed by western
blot for total (t) and phospho (p) specific Akt and GSK3b, as described
in Figure 3. The fold differences in the signals are marked.
Found at: doi:10.1371/journal.pone.0013121.s002 (1.56 MB TIF)
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